ProKidney PROK 深 沪
等待开盘 11-11 09:30:00 美东时间
1.11
-0.040
-3.48%
华盛通- 最 高1.165
- 今 开1.12
- 成交量 73.33万股
- 最 低 1.065
- 昨 收 1.15
- 总市值 3.36亿
- 52周最高 2.65
- 市盈率 静 --
- 换手率 0.24%
- 52周最低 0.8702
- 委 比 19.55%
- 总股本 3.02亿
- 历史最高 14.19
- 量 比 0.58
- 振 幅 8.70%
- 历史最低 0.4603
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ProKidney Announces At-the-Market Equity Offering Agreement
ProKidney ( ($PROK) ) just unveiled an announcement. On October 29, 2026, ProKi...
10-30 05:50
ProKidney Corp. Enters $200 Million At-The-Market Offering Agreement With Jefferies
On October 29, 2026, ProKidney Corp. (the "Company") entered into an Open Market Sale AgreementSM (the "Sales Agreement") with Jefferies LLC (the "Sales Agent"), pursuant to which the Company may offer and sell, from time to time, shares (the "Shares") of its Class A common stock, par value $0.0001 ...
10-30 05:37
美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.
10-29 04:47
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney Corp. will present eight abstracts, including one oral presentation, at the American Society of Nephrology’s Kidney Week 2026 in Denver. The abstracts highlight rilparencel's multifactorial mechanism of action, safety profile, and kidney function stabilization in advanced CKD and type 2 diabetes. The oral presentation focuses on graft-adjacent remodeling and vascular integrity in a CKD model. Other posters cover metabolic transitioning,...
10-22 12:00
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney Corp. will present eight abstracts, including one oral presentation, at the American Society of Nephrology’s Kidney Week 2026. The abstracts highlight rilparencel’s multifactorial mechanism of action in chronic kidney disease (CKD), with seven non-clinical studies showing evidence of oxidative damage attenuation, metabolic dysregulation, and pro-inflammatory signaling reduction. A clinical abstract presents Phase 2 data indicating safet...
10-02 13:00
ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $150.000 thousand w...
08-11 04:25
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday. Shares of Biohaven Ltd (NASDAQ:BHVN) fell sharply in pre-market trading. Biohaven announced enrollment of first patient in its pivotal Phase 3 trial of BHV-1300 for Graves’ disease. B of A Securi...
06-29 20:11
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy and maintains $12 price target.
05-18 22:59
